One of the most important developments in breast cancer, especially for people with hormone receptor-positive (HR+) advanced breast cancer, is the discovery and treatment of ESR1 mutations. These ...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that Inluriyo ( imlunestrant, Eli Lilly Nederland B.V.) be given marketing ...

CHICAGO -- The investigational oral agent vepdegestrant more than doubled median progression-free survival (PFS) versus fulvestrant (Faslodex) in previously treated estrogen receptor (ER)-positive ...

What Is Veppanu, and Why Does It Matter? Veppanu (vepdegestrant) is an oral cancer medicine for adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), ...

Rat disease models have played an integral role in scientific discovery and cancer research, including Nobel Prize–winning ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

Please provide your email address to receive an email when new articles are posted on . Vepdegestrant improved PFS for patients with ER-positive, HER2-negative advanced breast cancer with an ESR1 ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Breast cancer is one of the most common types of cancer in women in the United States. Each year, approximately 30% of newly diagnosed cancers in women are breast cancer. There are many treatments ...

Scientists at The Wistar Institute have solved a longstanding puzzle in ovarian cancer treatment: why anti-estrogen therapy often fails even when tumors express the hormone receptor that should make ...